These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 32233170

  • 1. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY.
    Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
    [Abstract] [Full Text] [Related]

  • 2. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 3. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y.
    J BUON; 2015 Jan; 20(3):847-54. PubMed ID: 26214639
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.
    Komiyama S, Kugimiya T, Kubushiro K.
    J Surg Oncol; 2018 Sep; 118(4):687-693. PubMed ID: 30206937
    [Abstract] [Full Text] [Related]

  • 5. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V, Moruzzi MC, Bizzarri N, Vargiu V, D'Indinosante M, Garganese G, Pasciuto T, Loverro M, Scambia G, Fagotti A.
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ, Chung YS, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
    [Abstract] [Full Text] [Related]

  • 7. Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
    Chou HH, Chen WC, Yang LY, Huang HJ, Chang WY, Lin H, Wu RC, Chen MY, Qiu JT, Huang KG, Chao A, Chang TC, Lai CH.
    Eur J Obstet Gynecol Reprod Biol; 2021 Jul; 262():13-20. PubMed ID: 33984725
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
    Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F.
    Eur J Cancer; 2017 Jan; 70():133-142. PubMed ID: 27914243
    [Abstract] [Full Text] [Related]

  • 9. Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.
    Shin W, Noh JJ, Seo SS, Kang S, Choi CH, Park SY, Kim BG, Lim MC.
    Yonsei Med J; 2020 Nov; 61(11):935-941. PubMed ID: 33107236
    [Abstract] [Full Text] [Related]

  • 10. Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.
    Machida H, Tokunaga H, Matsuo K, Matsumura N, Kobayashi Y, Tabata T, Kaneuchi M, Nagase S, Mikami M.
    Eur J Surg Oncol; 2020 May; 46(5):868-875. PubMed ID: 31818526
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
    Kusunoki S, Terao Y, Hirayama T, Fujino K, Ujihira T, Ota T, Takeda S.
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
    [Abstract] [Full Text] [Related]

  • 12. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Lim MC, Yoo HJ, Song YJ, Seo SS, Kang S, Kim SH, Yoo CW, Park SY.
    J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
    [Abstract] [Full Text] [Related]

  • 13. Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.
    Kim NK, Suh DH, Kim K, Kim YB, No JH.
    PLoS One; 2023 Jul; 18(4):e0284753. PubMed ID: 37083873
    [Abstract] [Full Text] [Related]

  • 14. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H, Japan Clinical Oncology Group.
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M, Sudo T, Iwasaki S, Ueno S, Wakahashi S, Yamaguchi S, Fujiwara K, Nishimura R.
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [Abstract] [Full Text] [Related]

  • 18. Clinical characteristics and treatment modalities in women with newly diagnosed advanced high-grade serous epithelial ovarian cancer in Taiwan.
    Hsu HC, Chou HH, Cheng WF, Chang CL.
    J Formos Med Assoc; 2024 Nov; 123(11):1167-1174. PubMed ID: 38453530
    [Abstract] [Full Text] [Related]

  • 19. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
    Liu YL, Zhou QC, Iasonos A, Filippova OT, Chi DS, Zivanovic O, Sonoda Y, Gardner G, Broach V, OCearbhaill R, Konner JA, Aghajanian CA, Long K, Tew W.
    Int J Gynecol Cancer; 2020 Oct; 30(10):1554-1561. PubMed ID: 32522770
    [Abstract] [Full Text] [Related]

  • 20. Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
    Iwasa-Inoue N, Nomura H, Kataoka F, Chiyoda T, Yoshihama T, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Morisada T, Hirasawa A, Aoki D.
    Int J Clin Oncol; 2022 Feb; 27(2):441-447. PubMed ID: 34648082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.